Enzalutamide(continued)
▶Enzalutamideis predicted to decrease the exposure to
panobinostat. Avoid.oTheoretical
▶Enzalutamideis predicted to decrease the exposure to
paritaprevir(with ritonavir and ombitasvir). Avoid.r
Study
▶Enzalutamideis predicted to decrease the exposure to
pazopanib. Avoid.rTheoretical
▶Enzalutamideis predicted to decrease the exposure to
phosphodiesterase type-5 inhibitors(avanafil, tadalafil). Avoid.
rStudy
▶Enzalutamideis predicted to decrease the exposure to
phosphodiesterase type-5 inhibitors(sildenafil, vardenafil).
oTheoretical
▶Enzalutamideis predicted to moderately to markedly decrease
the exposure topibrentasvir. Avoid.rStudy
▶Enzalutamideis predicted to moderately decrease the
exposure topitolisant.oStudy
▶Enzalutamideis predicted to decrease the exposure to
ponatinib. Avoid.oTheoretical
▶Enzalutamideis predicted to markedly decrease the exposure
topraziquantel. Avoid.oStudy
▶Enzalutamideis predicted to decrease the exposure to
quetiapine.oStudy
▶Enzalutamideis predicted to decrease the exposure to
ranolazine. Avoid.rStudy
▶Enzalutamideis predicted to decrease the exposure to
reboxetine.oAnecdotal
▶Enzalutamideis predicted to decrease the exposure to
regorafenib. Avoid.oStudy
▶Enzalutamideis predicted to decrease the exposure to
repaglinide. Monitor blood glucose and adjust dose.o
Study
▶Enzalutamideis predicted to markedly decrease the exposure
toribociclib. Avoid.rStudy
▶Enzalutamidemarkedly decreases the exposure torilpivirine.
Avoid.rStudy
▶Enzalutamideis predicted to decrease the exposure to
risperidone. Adjust dose.oStudy
▶Enzalutamideis predicted to moderately decrease the
exposure torivaroxaban. Avoid unless patient can be
monitored for signs of thrombosis.rStudy
▶Enzalutamideis predicted to decrease the exposure to
roflumilast. Avoid.oStudy
▶Enzalutamideis predicted to markedly decrease the exposure
torolapitant. Avoid.rStudy
▶Enzalutamideis predicted to decrease the exposure to
ruxolitinib. Monitor and adjust dose.oStudy
▶Enzalutamideis predicted to moderately decrease the
exposure tosaxagliptin.oStudy
▶Enzalutamideis predicted to decrease the exposure to
simeprevir. Avoid.rStudy
▶Enzalutamideis predicted to decrease the concentration of
sirolimus. Avoid.rStudy
▶Enzalutamideis predicted to decrease the exposure to
solifenacin.oTheoretical
▶Enzalutamideis predicted to decrease the exposure to
sorafenib.oTheoretical
▶Enzalutamideis predicted to decrease the exposure tostatins
(simvastatin).rStudy
▶Enzalutamideis predicted to decrease the exposure to
sunitinib. Avoid or adjustsunitinibdose.oStudy
▶Enzalutamidedecreases the concentration oftacrolimus.
Monitor and adjust dose.rStudy
▶Enzalutamideis predicted to decrease the exposure totaxanes
(cabazitaxel, paclitaxel). Avoid.rStudy
▶Enzalutamideis predicted to decrease the exposure totaxanes
(docetaxel).rTheoretical
▶Enzalutamideis predicted to decrease the concentration of
temsirolimus. Avoid.rStudy
▶Enzalutamidedecreases the exposure totetracyclines
(doxycycline). Monitor and adjust dose.oStudy
▶Enzalutamideis predicted to markedly decrease the exposure
toticagrelor. Avoid.rStudy▶Enzalutamideis predicted to decrease the exposure to
tivozanib.rStudy
▶Enzalutamideis predicted to decrease the exposure to
tofacitinib. Avoid.rStudy
▶Enzalutamideis predicted to decrease the exposure to
tolvaptan. Avoid.rStudy
▶Enzalutamideis predicted to decrease the exposure to
toremifene. Adjust dose.oStudy
▶Enzalutamideis predicted to decrease the exposure to
trabectedin. Avoid.rTheoretical
▶Enzalutamideis predicted to markedly decrease the exposure
toulipristal. Avoid and for 4 weeks after stoppingulipristal.
rTheoretical
▶Enzalutamideis predicted to decrease the exposure to
vandetanib. Avoid.oStudy
▶Enzalutamideis predicted to moderately decrease the
exposure tovelpatasvir. Avoid.rStudy
▶Enzalutamideis predicted to decrease the exposure to
vemurafenib. Avoid.rTheoretical
▶Enzalutamideis predicted to decrease the exposure to
venetoclax. Avoid.rStudy
▶Enzalutamideis predicted to decrease the exposure tovinca
alkaloids(vinblastine, vincristine, vindesine).rTheoretical
▶Enzalutamideis predicted to decrease the exposure tovinca
alkaloids(vinflunine). Avoid.rTheoretical
▶Enzalutamideis predicted to decrease the exposure tovinca
alkaloids(vinorelbine). Use with caution or avoid.r
Theoretical
▶Enzalutamideis predicted to decrease the exposure to
vismodegib. Avoid.oTheoretical
▶Enzalutamideis predicted to decrease the exposure to
vortioxetine. Monitor and adjust dose.oStudy
▶Enzalutamideis predicted to decrease the concentration of
voxilaprevir. Avoid.rStudy
▶Enzalutamideis predicted to decrease the exposure to
zopiclone. Adjust dose.oStudy
Ephedrine→see sympathomimetics, vasoconstrictor
Epirubicin→see anthracyclines
Eplerenone→see aldosterone antagonists
Epoetin alfa→seeTABLE 5p. 847 (thromboembolism),TABLE 16p. 851
(increased serum potassium)
Epoetin beta→seeTABLE 5p. 847 (thromboembolism),TABLE 16p. 851
(increased serum potassium)
Epoetin zeta→seeTABLE 5p. 847 (thromboembolism),TABLE 16p. 851
(increased serum potassium)
Epoprostenol→seeTABLE 4p. 847 (antiplatelet effects)
Eprosartan→see angiotensin-II receptor antagonists
Eptifibatide→seeTABLE 4p. 847 (antiplatelet effects)
Ergocalciferol→see vitamin D substances
Ergometrine
▶Antiarrhythmics(dronedarone)are predicted to increase the
risk of ergotism when given withergometrine.r
Theoretical
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the risk of ergotism when given with
ergometrine.rTheoretical
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the risk of ergotism when given with
ergometrine. Avoid.rTheoretical
▶Antifungals, azoles(miconazole)are predicted to increase the
exposure toergometrine. Avoid.oTheoretical
▶Aprepitantis predicted to increase the risk of ergotism when
given withergometrine.rTheoretical
▶Beta blockers, non-selectiveare predicted to increase the risk
of peripheral vasoconstriction when given withergometrine.
rStudy
▶Beta blockers, selectiveare predicted to increase the risk of
peripheral vasoconstriction when given withergometrine.
rStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the risk of ergotism when given withergometrine.
rTheoretical
▶Cobicistatis predicted to increase the risk of ergotism when
given withergometrine. Avoid.rTheoretical918 Enzalutamide—Ergometrine BNFC 2018 – 2019
Interactions|Appendix 1A1